Translational Research

TB Alliance and Partners Form Multidisciplinary Center for Translational TB Drug Research

The National Institute of Allergy and Infectious Diseases (NIAID) has awarded TB Alliance a Center of Excellence in Translational Research (CETR) grant (U19AI142735) for tuberculosis (TB) drug development. New translational research to develop novel anti-TB medicines is being carried out with partners at the University of Illinois at Chicago, Harvard University, Johns Hopkins University, and Research Triangle Institute.
  • NIAID’s CETR program was founded to support translational research activities ranging from early discovery-based efforts to late-stage preclinical development or medical countermeasures for emerging and re-emerging infectious diseases.
  • Potentially promising compounds have faced significant challenges in attracting the long-term funding needed to evaluate their potential safety and efficacy in treating people with TB. The estimated $1.3 billion annual funding gap for TB research and development is an obstacle to developing the new tools – including drugs – that are needed to end the global TB pandemic.
  • Find more information on the program here.



Learn more about TB Alliance projects in translational research:

  • TBA-7371, in partnership with the Foundation for Neglected Disease Research and the Bill & Melinda Gates Medical Research Institute
  • Innovative Medicines Initiative, a European public-private partnership enabling research to combat health threats, including drug-resistant tuberculosis